Subcutaneous Ocrelizumab Funded for Multiple Sclerosis
Pharmac have, today, announced they will fund subcutaneous ocrelizumab for multiple sclerosis. Multiple Sclerosis NZ and the wider MS community warmly welcome this landmark decision, bringing renewed hope to the lives of those affected by MS. We hope this decision is the first of many in improving patient experiences, access to treatments and system improvements. […]
More funded medicines for New Zealanders?
Media article: 19 May 2022 Pharmac welcomes the $191 million increase to its pharmaceutical budget over the next two years. It is already working its way through the medicines options for investment (OFI) list, looking at what agreements it can now make with pharmaceutical suppliers. “This budget increase is the biggest we’ve had since we […]